Ashley Hepner
Adult Health · Cleveland, OHNPI 1871894329
Payments from drug & device makers
Across 116 payments — averaging $52.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$421
- AbbVie$314
- Madrigal Pharmaceuticals$158
- QOL Medical, LLC$109
- Merck$88
- plus $435 from 14 others
What the payments were for
- Consulting fees$2,87047%
- Travel & lodging$92915%
- Food & beverage$2,28638%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 39 | $4,559 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $421 |
| AbbVie | 11 | $314 |
| Madrigal Pharmaceuticals | 7 | $158 |
| QOL Medical, LLC | 6 | $109 |
| Merck | 4 | $88 |
| Eisai Inc. | 3 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Intercept Pharmaceuticals, Inc. | 3 | $47 |
| Amgen | 3 | $45 |
| Novo Nordisk | 2 | $36 |
| AstraZeneca | 1 | $31 |
| Sandoz | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Pfizer | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Mirum Pharmaceuticals, Inc. | 1 | $18 |
| Exelixis Inc. | 1 | $17 |
| Dova Pharmaceuticals | 1 | $16 |
How this compares
$6,084 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MavyretGlecaprevir/Pibrentasvir | 11 | $143,443 |
| XifaxanRifaximin | 22 | $65,547 |
| Ursodiol | 25 | $834 |
| Furosemide | 11 | $74 |
| Pantoprazole Sodium | 11 | $35 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieMavyret | $314 | $143,44311 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $421 | $65,54722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.
Other adult health in Cleveland
- Susan FlickCleveland$131K
- Margaret TiktinCleveland$105K
- Kathleen HarrisCleveland$28K
- Mindy RiveraCleveland$20K
- Elizabeth CrespoCleveland$12K
- Amanda BonhamCleveland$7K
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.